DOTATATE PET Scan for Meningioma

(DOTATATE-RT Trial)

Overseen By Sandy Chang

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: British Columbia Cancer Agency

Disqualifiers: Pregnancy, Claustrophobia, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new method for diagnosing and planning treatment for central nervous system meningioma, a type of brain tumor. It uses a special PET scan with a substance called DOTATATE, which may show the tumor more clearly than an MRI. The goal is to improve radiation treatment by targeting the tumor more precisely while sparing healthy tissue. Individuals with meningioma who require radiation and have not received previous treatment might be suitable for this study.

As an unphased trial, this study provides a unique opportunity to contribute to innovative diagnostic methods that could enhance future treatment options.

Do I need to stop my current medications for the trial?

The trial protocol does not specify whether you need to stop taking your current medications.

What prior data suggests that the DOTATATE-PET scan is safe for diagnosing meningioma?

Research has shown that 68Ga-DOTATATE is generally safe for patients and aids in detecting meningiomas, a type of brain tumor. This compound binds to specific tumor sites not present in normal brain tissue, allowing doctors to see the tumor more clearly and plan treatment without affecting healthy areas.

No major reports of harmful side effects have emerged from using 68Ga-DOTATATE in imaging. It effectively helps doctors distinguish between tumor and non-tumor tissue, suggesting it is a safe imaging option for people with meningiomas. While more studies are ongoing, current evidence supports its safety for human use. ^{1 2 3 4 5}

Why are researchers excited about this trial?

The DOTATATE-PET scan is unique because it uses a special type of imaging that targets somatostatin receptors, which are often abundant in meningioma cells. Unlike traditional imaging methods like MRI or CT scans, DOTATATE-PET provides more precise and detailed pictures of the tumor, potentially leading to better diagnosis and treatment planning. Researchers are excited about this technique because it could help doctors pinpoint meningiomas more accurately, improving patient outcomes and possibly even leading to personalized treatment strategies.

What evidence suggests that DOTATATE-PET is effective for meningioma?

Research has shown that 68Ga-DOTATATE PET scans, which participants in this trial will undergo, are promising for detecting meningioma, a type of brain tumor. Studies have found that this imaging method accurately identifies tumors, with an accuracy rate of 86.7%. It surpasses MRI in revealing the complete size and shape of the tumor. This precision aids doctors in planning radiation therapy more accurately, reducing the risk of harming healthy brain tissue. Additionally, 68Ga-DOTATATE PET scans can distinguish between tumor regrowth and post-surgery changes, enhancing treatment accuracy. ^{1 2 3 4 6}

Are You a Good Fit for This Trial?

This trial is for individuals with meningioma, a type of brain tumor. Participants should be candidates for radiation therapy and can have any grade of meningioma. Specific eligibility criteria are not provided here, but typically include age, health status, and prior treatments.

Inclusion Criteria

Able and willing to comply with the study procedures

My meningioma has not been surgically removed and needs radiation.

I need additional radiation therapy after meningioma surgery.

Exclusion Criteria

Breastfeeding or pregnancy

Unwillingness or inability to provide informed consent

I cannot stay still or am claustrophobic.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

DOTATATE-PET Scan

Participants undergo a DOTATATE-PET scan for radiation planning

1 week

1 visit (in-person)

Radiation Planning and Treatment

Radiation therapy contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET

6-8 weeks

Follow-up

Participants are monitored for safety and effectiveness after radiation treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• DOTATATE-PET

Trial Overview

The study is testing if using a DOTATATE-PET scan before radiation therapy helps better plan the treatment for meningiomas compared to standard MRI scans alone. The goal is to see if this leads to more accurate targeting of tumors while sparing healthy tissue.

How Is the Trial Designed?

Group I: DOTATATE-PET scan Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

British Columbia Cancer Agency

Lead Sponsor

Trials

181

Recruited

95,900+

Published Research Related to This Trial

In a study of 20 patients with meningiomas, [68Ga]-DOTATATE PET/MRI successfully confirmed recurrent tumors in 85% of cases, demonstrating its effectiveness in distinguishing between tumor recurrence and post-treatment changes.

The novel quantitative analysis approach used in this study showed a significant difference in uptake values between meningiomas and post-treatment changes, suggesting that [68Ga]-DOTATATE PET/MRI could enhance diagnostic accuracy and treatment planning for meningioma patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Gallium-68 DOTATATE PET in the Evaluation of Intracranial Meningiomas. Ivanidze, J., Roytman, M., Lin, E., et al.[2020]

Citations

1.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC10337622/

Cost-Effectiveness Analysis of 68Ga-DOTATATE PET/MRI in ...

A recent diagnostic accuracy analysis of 68Ga-DOTATATE PET/MR imaging in 62 patients with meningiomas demonstrated a sensitivity and specificity of 86.7% and ...

2.

redjournal.org

redjournal.org/article/S0360-3016(22)00402-3/fulltext

68 Ga-DOTATATE PET: The Future of Meningioma Treatment

Potential benefits include improved diagnostic sensitivity, surgical planning, determination of the extent of resection, selection of RT target ...

3.

nature.com

nature.com/articles/s41598-022-13467-9

DOTATATE PET/MRI analysis in patients with meningioma

Further reinforcing its clinical utility, [68Ga]-DOTATATE PET has shown efficacy in predicting progression in non-benign meningioma as well as ...

4.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC7954102/

[68Ga]-DOTATATE PET/MRI as an adjunct imaging modality ...

SSTR2-targeted PET imaging with [ 68 Ga]-DOTATATE can aid with distinguishing residual meningioma from reactive changes in the postoperative setting.

5.

jnm.snmjournals.org

jnm.snmjournals.org/content/early/2025/08/07/jnumed.125.269633

[177Lu]Lu-DOTATATE for Recurrent Meningioma (LUMEN-1 ...

A more than 25% reduction in [68Ga]Ga-DOTATATE PET was observed in 5 meningiomas and 2 patients. In 1 lesion, this corresponded to a more than ...

6.

pubs.rsna.org

pubs.rsna.org/doi/full/10.1148/rycan.210067

Dynamic 68 Ga-DOTATATE PET/MRI in the Diagnosis and ...

Member of Data Safety Monitoring Board ... Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue.